Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FFAR1 | O14842 | 11/20 | 0.73 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.58 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.57 |
| ▸ | FFAR4 | Q5NUL3 | 3/20 | 0.57 |
| ▸ | PLAAT3 | P53816 | 1/20 | 0.56 |
| ▸ | PLAAT5 | Q96KN8 | 1/20 | 0.56 |
| ▸ | PLAAT2 | Q9NWW9 | 1/20 | 0.56 |
| ▸ | PLAAT4 | Q9UL19 | 1/20 | 0.56 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.53 |
| ▸ | PPARA | Q07869 | 1/20 | 0.52 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.51 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1454387 | 0.89 | FFAR1 (0.60) | FFAR1PDPK1PLAAT3PLAAT5PLAAT2 | |
| SCHEMBL30357702 | 0.88 | FFAR1 (0.60) | FFAR1PDPK1KEAP1FFAR4PLAAT3 | |
| SCHEMBL4037431 | 0.87 | HDAC1 (0.59) | FFAR1PDPK1PLAAT3PLAAT5PLAAT2 | |
| Hydrochloric Acid SCHEMBL2763476 | 0.87 | FFAR1 (0.59) | FFAR1PDPK1PLAAT3PLAAT5PLAAT2 | |
| SCHEMBL7332151 | 0.86 | FFAR1 (0.57) | FFAR1PDPK1PLAAT3PLAAT5PLAAT2 | |
| SCHEMBL23176837 | 0.85 | MAPT (0.62) | FFAR1PDPK1PPARAHDAC1HDAC8 | |
| SCHEMBL25172817 | 0.85 | MAPT (0.62) | FFAR1PDPK1PPARAHDAC1HDAC8 | |
| SCHEMBL7090409 | 0.85 | FFAR1 (0.61) | FFAR1PDPK1FFAR4PLAAT3PLAAT5 | |
| SCHEMBL11801516 | 0.84 | FFAR1 (0.55) | FFAR1PDPK1FFAR4PLAAT3PLAAT5 | |
| SCHEMBL10681264 | 0.83 | MLYCD (0.60) | FFAR1KEAP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 487 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-118184679-A | Photothermal agent and preparation method thereof, photothermal nanoparticle and preparation method thereof, insulating material and self-repairing method of insulating material | 中国石油天然气股份有限公司 | 2024-06-14 | — | — | CN | claimed |
| CN-115551846-B | 1,4,5, 6-tetrahydropyrimidin-2-amine derivatives | ＵＢＥ株式会社 | 2024-03-08 | — | — | CN | claimed |
| CN-114907288-B | Application of nitrobenzene compounds in preparation of pseudomonas aeruginosa quorum sensing inhibitor | 中国医学科学院医药生物技术研究所 | 2023-12-08 | — | — | CN | claimed |
| CN-117143097-A | Beta-carbopol compound, preparation method thereof and application of beta-carbopol compound in resisting Alzheimer disease | 中国人民解放军北部战区总医院 | 2023-12-01 | — | — | CN | claimed |
| WO-2023085396-A1 | PHARMACEUTICAL COMPOSITION FOR PROVIDING TREATMENT FOR OR PREVENTING ALPORT SYNDROME | ＵＢＥ株式会社 | 2023-05-19 | — | — | WO | claimed |
| CN-115551846-A | 1,4,5,6-tetrahydropyrimidin-2-amine derivatives | ＵＢＥ株式会社 | 2022-12-30 | — | — | CN | claimed |
| CN-115175907-A | Substituted piperazine derivatives useful as T cell activators | 百时美施贵宝公司 | 2022-10-11 | — | — | CN | claimed |
| CN-110167933-B | As αVAzole amides and amines as integrin inhibitors | 百时美施贵宝公司 | 2022-06-21 | — | — | CN | claimed |
| WO-2017092759-A1 | GEPHYRIN BINDING PEPTIDES AND USES THEREOF | UNIVERSITY OF COPENHAGEN (DK) | 2017-06-08 | — | — | WO | claimed |
| EP-3433239-B1 | SMALL MOLECULE INHIBITORS OF THE NUCLEAR TRANSLOCATION OF ANDROGEN RECEPTOR FOR THE TREATMENT OF CASTRATION-RESISTANT PROSTATE CANCER | UNIV PITTSBURGH COMMONWEALTH SYS HIGHER EDUCATION (US) | 2026-05-27 | — | — | EP | disclosed |
| US-20260028356-A1 | 1,3,4,7-TETRAHYDRO-2H-PYRROLO[3',2':5,6]PYRIDO[2,3-B][1,4]OXAZEPINE BCL-2 INHIBITORS | ABBVIE INC (US) | 2026-01-29 | — | — | US | disclosed |
| EP-4653451-A1 | POLYPEPTIDE COMPOUND AND USE THEREOF | Chengdu New Radiomedicine Technology Co., Ltd. (CN) | 2025-11-26 | — | — | EP | disclosed |
| US-20250353863-A1 | TRICYCLIC SPIROLACTAM COMPOUNDS WITH ANTIMYCOBACTERIAL ACTIVITY | INST NAT SANTE RECH MED (FR) | 2025-11-20 | — | — | US | disclosed |
| WO-2025224599-A1 | PYRROLIDINE-BASED GLUCOSE-DEPENDENT INSULINOTROPIC POLYPEPTIDE RECEPTOR ANTAGONISTS AND USES THEREOF | PFIZER INC. (US) | 2025-10-30 | — | — | WO | disclosed |
| US-4970328-A | MITICIDE, FUNGICIDE | BAYER AKTIENGESELLSCHAFT (DE) | 1990-11-13 | — | — | US | disclosed |
| US-4957533-A | THIOAMIDES, AMIDINES | ELI LILLY AND COMPANY (US) | 1990-09-18 | — | — | US | disclosed |
| WO-1990006937-A1 | DERIVATIVES OF TETRAPEPTIDES AS CCK AGONISTS | ABBOTT LABORATORIES (US) | 1990-06-28 | — | — | WO | disclosed |
| US-4929642-A | MITICIDES, FUNGICIDES | BAYER AKTIENGESELLSCHAFT (DE) | 1990-05-29 | — | — | US | disclosed |
| EP-0314422-A2 | N-phenylalkylbenzamide fungicides | DOWELANCO (US) | 1989-05-03 | — | — | EP | disclosed |
| EP-0300218-A1 | Use of substituted 1,4-naphthoquinones against nites and fungi | BAYER AG (DE) | 1989-01-25 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260028356-A1 | 1,3,4,7-TETRAHYDRO-2H-PYRROLO[3',2':5,6]PYRIDO[2,3-B][1,4]OXAZEPINE BCL-2 INHIBITORS | BCL9L, BCL2L2, BCL2L1 | FFAR1 1483/4885PDPK1 1623/4885KEAP1 2884/4885 |
| US-20250353863-A1 | TRICYCLIC SPIROLACTAM COMPOUNDS WITH ANTIMYCOBACTERIAL ACTIVITY | TALDO1, TBCA, TBCD | FFAR1 3772/4885PDPK1 1248/4885KEAP1 765/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.